Plain-English translation of NCT07041801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a Phase 1/2 clinical trial testing human umbilical cord mesenchymal stem cell injections (hUCMSCs) as a potential treatment for moderate to severe systemic lupus erythematosus (SLE). Researchers want to learn whether these stem cells, combined with your regular lupus medications, can reduce inflammation and improve your symptoms. The trial will test four different doses of the medication, plus a comparison group receiving only standard treatment.
Lupus is a serious autoimmune disease where your body attacks its own tissues, causing pain, inflammation, and organ damage. Current treatments help some patients but not all, and researchers believe stem cells may have special healing properties that could calm the immune system and reduce lupus activity.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive one of four different doses of stem cell injections, or a placebo injection, along with your regular lupus medications. The stem cells will be injected into your body over time. You will visit the clinic for injections and follow-up appointments to have your blood tested, be evaluated for symptoms, and monitored for any side effects. The full duration of the trial and visit schedule will be explained to you in detail before you decide to enroll.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China